Recent News

• 04.21.2025 - ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
• 04.21.2025 - ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
• 04.10.2025 - ReShape Strategic Business Update
• 04.10.2025 - ReShape Strategic Business Update
• 04.09.2025 - ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
• 04.09.2025 - ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
• 04.07.2025 - ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
• 04.07.2025 - ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
• 03.10.2025 - ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
• 03.10.2025 - ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Recent Filings

• 04.04.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.04.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.02.2025 - 8-K Current report
• 04.01.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
• 03.20.2025 - 8-K Current report
• 03.14.2025 - DEF 14A Other definitive proxy statements
• 03.13.2025 - PRER14A Preliminary Proxy Soliciting materials
• 03.03.2025 - PRE 14A Other preliminary proxy statements